nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

16.05.2020 | Original Article

The epidemiology of invasive meningococcal disease and the utility of vaccination in Malta

verfasst von: David Pace, Charmaine Gauci, Christopher Barbara

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Invasive meningococcal disease (IMD) is a vaccine-preventable devastating infection that mainly affects infants, children and adolescents. We describe the population epidemiology of IMD in Malta in order to assess the potential utility of a meningococcal vaccination programme. All cases of microbiologically confirmed IMD in the Maltese population from 2000 to 2017 were analysed to quantify the overall and capsular-specific disease burden. Mean overall crude and age-specific meningococcal incidence rates were calculated to identify the target age groups that would benefit from vaccination. Over the 18-year study period, 111 out of the 245 eligible notified cases were confirmed microbiologically of which 70.3% had septicaemia, 21.6% had meningitis, and 6.3% had both. The mean overall crude incidence rate was 1.49/100,000 population with an overall case fatality rate of 12.6%. Meningococcal capsular groups (Men) B followed by C were the most prevalent with W and Y appearing over the last 6 years. Infants had the highest meningococcal incidence rate of 18.9/100,000 followed by 6.1/100,000 in 1–5 year olds and 3.6/100,000 in 11–15 year old adolescents. The introduction of MenACWY and MenB vaccines on the national immunization schedule in Malta would be expected to reduce the disease burden of meningococcal disease in children and adolescents in Malta.

ECDC: European Centre for Disease Prevention and Control. Surveillance Report. Invasive meningococcal disease. Annual Epidemiological Report for 2017. Stockholm 2019. Available from https://ecdc.europa.eu/sites/portal/ files/documents/AER_for_2017-invasive-meningococcal-disease.pdf. Accessed 20^th April, 2020

CDC: Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs). Surveillance reports: Neisseria meningitidis, 1997–2017. Available from http://www.cdc.gov/abcs/reports-findings/surv-reports.html. Accessed 20th April, 2020

Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H (2019) Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 37(21):2768–2782PubMed

Sadarangani M, Scheifele DW, Halperin SA, Vaudry W, Le Saux N, Tsang R, Bettinger JA (2015) Investigators of the Canadian Immunization Monitoring Program, ACTive (IMPACT). Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study. Clin Infect Dis 60(8):e27–e35PubMed

Davis KL, Misurski D, Miller J, Karve S (2011) Cost impact of complications in meningococcal disease: evidence from a United States managed care population. Hum Vaccin 7(4):458–465PubMed

Stein-Zamir C, Shoob H, Sokolov I, Kunbar A, Abramson N, Zimmerman D (2014) The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis 33(7):777–779

Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, Kaczmarski E, Rajput K, Ramsay M, Christie D (2012) Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 11(9):774–783PubMed

Mohammed I, Iliyasu G, Habib AG (2017) Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa. Pathog Glob Health 111:1–6PubMedPubMedCentral

Kretz CB, Retchless AC, Sidikou F, Issaka B, Ousmane S, Schwartz S, Tate AH, Pana A, Njanpop-Lafourcade BM, Nzeyimana I et al (2016) Whole-genome characterization of epidemic Neisseria meningitidis serogroup C and resurgence of serogroup W, Niger, 2015. Emerg Infect Dis 22:1762–1768PubMedPubMedCentral

10.

Delrieu I, Yaro S, Tamekloe TA, Njanpop-Lafourcade BM, Tall H, Jaillard P, Ouedraogo MS, Badziklou K, Sanou O, Drabo A et al (2011) Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 6:e19513PubMedPubMedCentral

11.

Yezli S (2018) The threat of meningococcal disease during the Hajj and Umrah mass gatherings: a comprehensive review. Travel Med Infect Dis 24:51–58PubMed

12.

Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364(9431):365–367PubMed

13.

de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A (2006) Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 25(1):79–80PubMed

14.

Larrauri A, Cano R, García M, de Mateo S (2005) Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23(32):4097–4100PubMed

15.

do Macedo LE, Ferreira VM, Feitosa CA, Nunes AMPB, Campos LC, Sáfadi MAP (2018) Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: lessons learned from Bahia. Brazil Hum Vaccin Immunother 14(5):1131–1137

16.

Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-Benissan C, Ronveaux O, Preziosi MP, Stuart JM (2017) Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data. Lancet Infect Dis 17:867–872PubMed

17.

Villena R, Valenzuela MT, Bastías M, Santolaya ME (2019) Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile. Vaccine. 37(46):6915–6921PubMed

18.

Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM, Maiden MCJ, Ladhani SN, Ramsay ME, Trotter C, Borrow R, Finn A, Kahler CM, Whelan J, Vadivelu K, Richmond P (2020) Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med 382(4):318–327PubMed

19.

McNamara LA, Thomas JD, MacNeil J, Chang HY, Day M, Fisher E, Martin S, Poissant T, Schmink SE, Steward-Clark E, Jenkins LT, Wang X (2017) Acosta ; Oregon Meningococcal Carriage Team. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a universityserogroup B meningococcal disease outbreak-Oregon, 2015-2016. J Infect Dis 216(9):1130–1140PubMedPubMedCentral

20.

National Statistics Office, Malta. Regional Statistics Malta 2019. Available from www.nso.gov.mt. Accessed 17th July, 2019

21.

National Statistics Office, Malta. 2014. Census of Population and Housing, 2011. Available from www.nso.gov.mt. Accessed 7th October, 2019

22.

The European Commission. Official Journal of the European Union. Decisions. 2012/506/EU; L262:1–56

23.

Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, Mallard RH, Kaczmarski EB (2006) Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the meningococcal reference unit. J Med MicrobiolJ 55(Pt 7):887–896

24.

The Commission of the European Communities. Official Journal of the European Communities. 2002/253/EC;L86:44–62

25.

The Commission of the European Communities. Commission Decision. 28/IV/2008;1–79

26.

EU-IBIS Network: European Union Invasive Bacterial Infections Surveillance Network. Invasive Neisseria meningitidis in Europe 2003/2004. Health Protection Agency, London 2006. Available from www.euibis.org. Accessed 10th June, 2016

27.

EU-IBIS Network: European Union Invasive Bacterial Infections Surveillance Network. Invasive Neisseria meningitidis in Europe 2006. Health Protection Agency, London 2006. Available from www.euibis.org. Accessed 20^th April, 2020

28.

ECDC: European Centre for Disease Prevention and Control. Surveillance network for invasive Neisseria meningitidis in Europe – 1999 & 2000. ECDC 2007. Available from http://www.ecdc.europa.eu. Accessed 20^th April, 2020

29.

European Centre for Disease Prevention and Control. Invasive meningococcal disease. Annual Epidemiological Report on communicable diseases in Europe (2007) Reporting on 2005 surveillance data. ECDC, Stockholm

30.

European Centre for Disease Prevention and Control. Annual Epidemiological Report. Reporting on 2007–2011 surveillance data. Stockholm: ECDC; 2009–2013

31.

European Centre for Disease Prevention and Control. Annual epidemiological report 2014 – vaccine-preventable diseases – invasive bacterial diseases. Stockholm: ECDC; 2015

32.

European Centre for Disease Prevention and Control. Invasive meningococcal disease. In: ECDC. Annual epidemiological reports for 2015–2017. Stockholm: ECDC; 2016–2019

33.

ECDC: European Centre for Disease Prevention and Control. Vaccine Scheduler. Available at http://vaccine-schedule.ecdc.europa.eu Accessed 20^th April, 2020

34.

Burman C, Serra L, Nuttens C, Presa J, Balmer P, York L (2019) Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. Hum Vaccin Immunother 15(2):459–469PubMed

35.

(2007) Centers for Disease Control and Prevention. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine. MMWR 56:794–795

36.

Page AL, Coldiron ME, Gamougam K, Acyl MA, Tamadji M, Lastrucci C, Hurtado N, Tehoua FC, Fermon F, Caugant DA, Porten K (2017) Four years of case-based surveillance of meningitis following the introduction of MenAfriVac in Moissala, Chad: lessons learned. Trop Med Int Health 22(12):1561–1568PubMed

37.

Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME (2020) Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med 382(4):309–317PubMed

38.

Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, Cieslak P, Shutt KA, Popovic T, Schuchat A, Harrison LH, Reingold AL (1999) The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 180(6):1894–1901PubMed

39.

Galdies C (2011) The Climate of Malta: statistics, trends and analysis 1951-2010. National Statistics Office, Malta

40.

Kinlin LM, Spain CV, Ng V, Johnson CC, White AN, Fisman DN (2009) Environmental exposures and invasive meningococcal disease: an evaluation of effects on varying time scales. Am J Epidemiol 169(5):588–595PubMedPubMedCentral

41.

Malta Tourism Authority. Tourism in Malta. Editions 2015 to 2017

42.

Cartwright KA, Stuart JM, Jones DM, Noah ND (1987) The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 99(3):591–601PubMedPubMedCentral

43.

MacLennan J, Kafatos G, Neal K, Andrews N, Cameron JC, Roberts R, Evans MR, Cann K, Baxter DN, Maiden MC, Stuart JM, United Kingdom meningococcal carriage group (2006) Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis 12(6):950–957PubMedPubMedCentral

44.

Breakwell L, Whaley M, Khan UI, Bandy U, Alexander-Scott N, Dupont L, Vanner C, Chang HY, Vuong JT, Martin S, MacNeil JR, Wang X, Meyer SA (2018) Meningococcal carriage among a university student population - United States, 2015. Vaccine. 36(1):29–35PubMed

45.

van Ravenhorst MB, Bijlsma MW, van Houten MA, Struben VMD, Anderson AS, Eiden J, Hao L, Jansen KU, Jones H, Kitchin N, Pedneault L, Sanders EAM, van der Ende A (2017) Meningococcal carriage in Dutch adolescents and young adults; a cross-sectional and longitudinal cohort study. Clin Microbiol Infect 23(8):573.e1–573.e7

46.

Díaz J, Cárcamo M, Seoane M, Pidal P, Cavada G, Puentes R, Terrazas S, Araya P, Ibarz-Pavon AB, Manríquez M, Hormazábal JC, Ayala S, Valenzuela MT (2016) Prevalence of meningococcal carriage in children and adolescents aged 10-19 years in Chile in 2013. J Infect Public Health 9(4):506–515PubMed

47.

Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN (2016) Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 388(10061):2775–2782PubMed

48.

Trotter C, Borrow R, Andrews N, Miller E (2003) Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine. 21(11–12):1094–1098PubMed

49.

Jansen AG, Sanders EA, Van Der Ende A, Van Loon AM, Hoes AW, Hak E (2008) Invasive pneumococcal and meningococcal disease: association with influenza virus and respiratory syncytial virus activity? Epidemiol Infect 136(11):1448–1454PubMedPubMedCentral

50.

Bröker M, Emonet S, Fazio C, Jacobsson S, Koliou M, Kuusi M, Pace D, Paragi M, Pysik A, Simões MJ, Skoczynska A, Stefanelli P, Toropainen M, Taha MK, Tzanakaki G (2015) Meningococcal serogroup Y disease in Europe: continuation of high importance in some European regions in 2013. Hum Vaccin Immunother 11(9):2281–2286PubMedPubMedCentral

51.

Glode MP, Robbins JB, Liu TY, Gotschlich EC, Orskov I, Orskov F (1977) Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92. J Infect Dis 135(1):94–104PubMed

52.

Troncoso G, Sánchez S, Moreda M, Criado MT, Ferreirós CM (2000) Antigenic cross-reactivity between outer membrane proteins of Neisseria meningitidis and commensal Neisseria species. FEMS Immunol Med Microbiol 27(2):103–109PubMed

53.

Siegrist CA, Aspinall R (2009) B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 9(3):185–194PubMed

54.

Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, Craig AS, Farley M, Gershman K, Petit S, Lynfield R, Reingold A, Schaffner W, Shutt KA, Zell ER, Mayer LW, Clark T, Stephens D, Messonnier NE (2010) Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 50(2):184–191PubMed

55.

Waśko I, Hryniewicz W, Skoczyńska A (2015) Significance of meningococcal hyperinvasive clonal complexes and their influence on vaccines development. Pol J Microbiol 64(4):313–321PubMed

56.

Jelfs J, Munro R, Ashto FE, Caugant DA (2000) Genetic characterization of a new variant within the ET-37 complex of Neisseria meningitidis associated with outbreaks in various parts of the world. Epidemiol Infect 125(2):285–298PubMedPubMedCentral

57.

Jandova Z, Musilek M, Vackova Z, Kozakova J, Krizova P (2016) Serogroup and clonal characterization of Czech invasive Neisseria meningitidis strains isolated from 1971 to 2015. PLoS One 11(12):e0167762PubMedPubMedCentral

58.

Jounio U, Saukkoriipi A, Bratcher HB, Bloigu A, Juvonen R, Silvennoinen-Kassinen S, Peitso A, Harju T, Vainio O, Kuusi M, Maiden MC, Leinonen M, Käyhty H, Toropainen M (2012) Genotypic and phenotypic characterization of carriage and invasive disease isolates of Neisseria meningitidis in Finland. J Clin Microbiol 50(2):264–273PubMedPubMedCentral

59.

GlaxoSmithKline Vaccines (2019) Summary of product characteristics: Bexsero meningococcal group B vaccine for injection in pre-filled syringe. Available from www.medicines.org.uk. Accessed 17^th October, 2019

60.

Pfizer Ltd (2018) Summary of product characteristics: Trumenba. Available from www.medicines.org.uk. Accessed 20^th April, 2020

61.

Arnold R, Galloway Y, McNicholas A, O'Hallahan J (2011) Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine. 29(40):7100–7106PubMed

62.

Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J (2009) Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 38(2):413–418PubMed

63.

Martinón-Torres F, Nolan T, Toneatto D, Banzhoff A (2019) Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults. Hum Vaccin Immunother 9:1–12

64.

Borrow R, Goldblatt D, Andrews N, Southern J, Ashton L, Deane S, Morris R, Cartwright K, Miller E (2002) Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis 186(9):1353–1357PubMed

65.

Pace D, Khatami A, McKenna J, Campbell D, Attard-Montalto S, Birks J, Voysey M, White C, Finn A, Macloed E, Faust SN, Kent AL, Heath PT, Borrow R, Snape MD, Pollard AJ (2015;350:h1554. Erratum in: BMJ. 2016 May 06) Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. BMJ 353:i2605

66.

Khatami A, Snape MD, Davis E, Layton H, John T, Yu LM, Dull PM, Gill CJ, Odrjlin T, Dobson S, Halperin SA, Langley JM, McNeil SA, Pollard AJ (2012) Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine. 30(18):2831–2838PubMed

67.

Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM (2016) Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Hum Vaccin Immunother 12(1):132–139PubMed

68.

Wormsbecker AE, Wong K, Jamieson FB, Crowcroft NS, Deeks SL (2015) Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: vaccine program impact assessment. Vaccine. 33(42):5678–5683PubMed

69.

Kaaijk P, van der Ende A, Berbers G, van den Dobbelsteen GP, Rots NY (2012) Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? Experience from the Netherlands. BMC Infect Dis 12:35PubMedPubMedCentral

70.

Campbell H, Borrow R, Salisbury D, Miller E (2009) Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 27(Suppl 2):B20–B29PubMed

Titel: The epidemiology of invasive meningococcal disease and the utility of vaccination in Malta
verfasst von: David Pace
Charmaine Gauci
Christopher Barbara
Publikationsdatum: 16.05.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 10/2020
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-020-03914-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The epidemiology of invasive meningococcal disease and the utility of vaccination in Malta

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Drei Mythen bei der Antibiotikatherapie

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2020

Septic shock caused by Capnocytophaga canis after a cat scratch

First report of Tsukamurella endocarditis in an immunocompromised patient receiving chemotherapy

Leprosy in the twenty-first century: a microbiological, clinical, and epidemiological study in northwestern Spain

Relationships among streptococci from the mitis group, misidentified as Streptococcus pneumoniae

Changing epidemiology and resistance patterns of pathogens causing neonatal bacteremia

Standardization of ELISA for anti-chikungunya-IgG antibodies and age-stratified prevalence of anti-chikungunya-IgG antibodies in Pune, India

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Drei Mythen bei der Antibiotikatherapie

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Update Innere Medizin